To analyze the intracellular effects upon TMZ+AT101/AT101 therapy in surviving, MGMT promoter-methylated mono- and co-cultured GBM cells, respectively, we first performed a human MAPK (mitogen-activated protein kinase) phosphorylation antibody array of the respective GBM cells (PCa) after 3 days of stimulation (example depicted in Figure 2A). This evidence concerns the gene WNK2 and posterior cortical atrophy.